From: Is cycle network expansion cost-effective? A health economic evaluation of cycling in Oslo
Age | Mortality rate [26] | |||||||
---|---|---|---|---|---|---|---|---|
T2D | Cancer | Stroke | CHD | CVD | All-cause | CHD | Stroke | |
30–34 | 0.0016 | 0.0011 | 0.0003 | 0.0001 | 0.00002 | 0.00046 | 0.0877 | 0.2346 |
35–39 | 0.0018 | 0.0016 | 0.0005 | 0.0003 | 0.00005 | 0.00059 | 0.0877 | 0. 2346 |
40–44 | 0.0031 | 0.0022 | 0.0010 | 0.0006 | 0.0001 | 0.00082 | 0.0877 | 0. 2346 |
45–49 | 0.0050 | 0.0035 | 0.0017 | 0.0010 | 0.0002 | 0.00136 | 0.0877 | 0. 2346 |
50–54 | 0.0076 | 0.0058 | 0.0025 | 0.0018 | 0.0004 | 0.00231 | 0.0877 | 0. 2346 |
55–59 | 0.0098 | 0.0087 | 0.0033 | 0.0029 | 0.0007 | 0.00384 | 0.1155 | 0.2328 |
60–64 | 0.0106 | 0.0134 | 0.0044 | 0.0046 | 0.0011 | 0.00610 | 0.1155 | 0.2328 |
65–69 | 0.0105 | 0.0190 | 0.0056 | 0.0069 | 0.0020 | 0.01052 | 0.2107 | 0.2347 |
70+ | 0.0121 | 0.0252 | 0.0070 | 0.0102 | 0.0036 | 0.01742 | 0.2107 | 0.2347 |